Payment overview · 2025
General Payments
$1,003.09
56 reported records · 20 companies
Healthcare provider profile · identity verified
Muhammad Farhan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MT STERLING, KY · NPI 1962748541
Verified facts
What the public records show
CMS Open Payments records show Muhammad Farhan, M.D. received $1,003.09 in general payments during 2025 across 56 reported records.
Amgen Inc. accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Jynarque, Kerendia, Linzess, Ozempic, Trelegy Ellipta, Velphoro, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Kerendia by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Velphoro by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 11133 records involving 4164 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jynarque by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $301.36 | 30.0% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.04 | 8.4% | 4 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $75.88 | 7.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.53 | 7.0% | 3 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $65.58 | 6.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.83 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.02 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.71 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.30 | 3.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.17 | 3.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.01 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.67 | 3.0% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.30 | 2.6% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $25.11 | 2.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.86 | 2.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.62 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.13 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.89 | 1.6% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $13.73 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.35 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $937.51 | 52 |
| Education | $65.58 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $116.47 | 5 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $93.73 | 8 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $84.04 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $75.88 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $70.53 | 3 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $63.74 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.87 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.02 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.50 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 195 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| JYNARQUE jynarque |
2025 | Jynarque | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 209 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 122 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
195 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
209 | 49 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 11133 supporting records · 4164 recipient NPIs · example record 1227267725 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 543 | 111 |
| Losartan Potassium | Losartan Potassium | 479 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 451 | 123 |
| Omeprazole | Omeprazole | 397 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 98 |
| Trazodone Hcl | Trazodone Hcl | 375 | 75 |
| Lisinopril | Lisinopril | 371 | 101 |
| Potassium Chloride | Potassium Chloride | 370 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 323 | 81 |
| Bumetanide | Bumetanide | 304 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 81 |
| Torsemide | Torsemide | 288 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 277 | 40 |
| Allopurinol | Allopurinol | 273 | 63 |
| Eliquis | Apixaban | 266 | 58 |
| Metformin Hcl | Metformin Hcl | 253 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 239 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 56 |
| Glipizide | Glipizide | 225 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 80 |
| Alprazolam | Alprazolam | 209 | 56 |
| Ozempic | Semaglutide | 209 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 51 |
| Amitriptyline Hcl | Amitriptyline Hcl | 199 | 50 |
| Farxiga | Dapagliflozin Propanediol | 195 | 50 |
| Nifedipine Er | Nifedipine | 190 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 52 |
| Prednisone | Prednisone | 177 | 73 |
| Tramadol Hcl | Tramadol Hcl | 175 | 49 |
| Ondansetron Hcl | Ondansetron Hcl | 174 | 53 |
| Sertraline Hcl | Sertraline Hcl | 172 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 160 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 152 | 41 |
| Chlorthalidone | Chlorthalidone | 146 | 44 |
| Finasteride | Finasteride | 146 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 47 |
| Carvedilol | Carvedilol | 138 | 39 |
| Buspirone Hcl | Buspirone Hcl | 136 | 27 |
| Mirtazapine | Mirtazapine | 134 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 43 |
| Montelukast Sodium | Montelukast Sodium | 131 | 43 |
| Valsartan | Valsartan | 127 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 125 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 122 | 27 |
| Clonazepam | Clonazepam | 117 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 104 | 31 |
| Jardiance | Empagliflozin | 104 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 19 |
| Midodrine Hcl | Midodrine Hcl | 101 | 17 |
| Januvia | Sitagliptin Phosphate | 98 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 17 |
| Furosemide | Furosemide | 88 | 21 |
| Simvastatin | Simvastatin | 83 | 28 |
| Lactulose | Lactulose | 80 | 25 |
| Dextrose In Water | Dextrose 5 % In Water | 78 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 60 |
| Bupropion Hcl | Bupropion Hcl | 76 | 18 |
| Promethazine Hcl | Promethazine Hcl | 76 | 18 |
| Clonidine | Clonidine | 74 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Spironolactone | Spironolactone | 68 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 65 | 16 |
| Famotidine | Famotidine | 63 | 19 |
| Meloxicam | Meloxicam | 62 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 19 |
| Donepezil Hcl | Donepezil Hcl | 58 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 16 |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 44 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Sucralfate | Sucralfate | 54 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 53 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Lorazepam | Lorazepam | 51 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 13 |
| Fluconazole | Fluconazole | 50 | 32 |
| Lovastatin | Lovastatin | 50 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 43 |
| Ibuprofen | Ibuprofen | 47 | suppressed |
| Vraylar | Cariprazine Hcl | 47 | suppressed |
| Glipizide Er | Glipizide | 46 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 44 | 13 |
| Naloxone Hcl | Naloxone Hcl | 44 | 13 |
| Linzess | Linaclotide | 43 | suppressed |
| Nystatin | Nystatin | 43 | 24 |
| Kerendia | Finerenone | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | 14 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 17 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Roflumilast | Roflumilast | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Cilostazol | Cilostazol | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | 11 |
| Diazepam | Diazepam | 23 | 11 |
| Metolazone | Metolazone | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Jynarque | Tolvaptan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Xphozah | Tenapanor Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,003.09 · 56 records | Amgen Inc. | AREXVY, CREON, FARXIGA, Fabhalta, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LINZESS, MINIMED 780G, OTEZLA, Ohtuvayre, Ozempic, RAYALDEE, REPATHA, SHINGRIX, TARPEYO, TAVNEOS, TRELEGY ELLIPTA, UPLIZNA, VELPHORO, VERQUVO, VOQUEZNA, VRAYLAR, Vanrafia, Veltassa, XIFAXAN | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error